Skip to main content

Table 4 Screening coverage rate

From: Cost-benefit analysis of Chlamydia trachomatis screening in pregnant women in a high burden setting in the United States

 

100% (base case analysis)

90%

80%

70%

60%

Cost a

256,305,162

245,671,430

221,104,287

207,838,030

182,900189

SAB

3

32

38

49

54

Pneumonia

3,093

3,351

4,021

5,027

5,530

PID

6,393

6,896

7,585

8,344

9,467

Neonatal Conjunctivitis

6,806

7,366

8,471

9,318

10,996

Vertical Transmission

8,211

8,533

9,642

10,563

12,042

Treated Chlamydia

496,241

431,794

362,707

333,690

296,941

Premature

3

28

31

36

43

Infertility

380

841

925

1,111

1,155

  1. Outcomes of all endpoints when the % of total women screened by program was varied between 60–100%
  2. SAB spontaneous abortion, PID pelvic inflammatory disease
  3. aCosts expressed in 2015 USD